Digestive System Fistula Pipeline Analysis Report 2026

Fistulizing disorders represent a complex and high-burden complication in the digestive system therapeutic landscape, particularly in inflammatory bowel disease populations. Globally, up to 35% of patients with Crohn’s disease may develop fistulas during their lifetime, highlighting a substantial unmet need for durable treatment options. The digestive system fistula pipeline analysis underscores increasing clinical focus on regenerative cell therapies, advanced biologics, and targeted immunomodulators aimed at improving closure rates and reducing recurrence in these challenging gastrointestinal conditions.

Report Coverage

The Digestive System Fistula Pipeline Analysis Report gives comprehensive insights into digestive system fistula therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for digestive system fistula. The digestive system fistula report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The digestive system fistula pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with digestive system fistula treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to digestive system fistula.

Digestive System Fistula Pipeline Outlook

The pipeline outlook reflects growing innovation aimed at improving outcomes in complex and refractory cases. Standard management typically includes antibiotics, nutritional optimization, drainage procedures, and surgery, while biologics such as anti-TNF monoclonal antibodies are commonly used in Crohn’s-associated fistulas. However, high recurrence rates and incomplete healing continue to drive therapeutic advancement. In February 2025, the U.S. Food and Drug Administration granted Fast Track designation to AVB-114, an implantable cell therapy developed by Avobis Bio LLC for Crohn’s-related perianal fistulas, underscoring regulatory support for regenerative approaches addressing significant unmet clinical needs.

Digestive System Fistula Epidemiology

Digestive system fistulas represent a significant clinical challenge worldwide, often arising from conditions such as inflammatory bowel disease and surgical complications. In Crohn’s disease, up to 35% of patients develop fistulas during their disease course, with perianal and enterocutaneous fistulas common in affected populations. Enterocutaneous fistulas have a varied incidence depending on etiology, with surgical causes predominating. Gastrointestinal fistulas occur in roughly 11.7% of U.S. Crohn’s patients, including anal, rectovaginal, and internal connections. Global prevalence estimates vary by type and region, underscoring the multifactorial nature and widespread burden of fistulizing disease.

Digestive System Fistula - Pipeline Therapeutic Assessment

This section of the report covers the analysis of digestive system fistula drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The digestive system fistula pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Cell Therapies

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Digestive System Fistula Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total digestive system fistula clinical trials. Phase II represents 40% of digestive system fistula trials, followed by phase I at 30%. Phase III and phase IV each account for 15%, indicating encouraging progress and growing momentum in digestive system fistula drug development.

Digestive System Fistula Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the digestive system fistula pipeline analysis include small molecules, monoclonal antibodies, and cell therapies. The digestive system fistula report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for digestive system fistula. In July 2024, Signum Surgical’s BioHealx™ technology received De Novo clearance from the U.S. Food and Drug Administration as a first-of-its-kind, single-use bioabsorbable implant for the treatment of anal fistula, offering a minimally invasive option designed to close the fistula tract and promote healing after prior failed therapies.

Digestive System Fistula Clinical Trials - Key Players

The report for the Digestive System Fistula pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed digestive system fistula therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in digestive system fistula clinical trials:

• Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
• Lynch Regenerative Medicine, LLC
• Angiocrine Bioscience
• RedHill Biopharma
• Amgen
• Celgene
• Abivax
• Gilead Sciences
• Arena Pharmaceuticals
• Prometheus Biosciences

Digestive System Fistula - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for digestive system fistula. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of digestive system fistula drug candidates.

Drug: E-CEL UVEC

E-CEL UVEC is an allogeneic umbilical vein endothelial cell-based therapy belonging to the regenerative cell therapy class, developed by Jiangsu Topcel-KH Pharmaceutical Co., Ltd. The candidate is designed to promote angiogenesis and tissue repair within fistula tracts by enhancing microvascular formation and supporting local wound healing. By improving blood supply and modulating inflammatory responses, E-CEL UVEC aims to accelerate durable closure of digestive system fistulas. Jiangsu Topcel-KH focuses on advanced cellular platforms and translational regenerative medicine research to expand therapeutic applications globally.

Drug: AdMSC (CellReady®)

AdMSC (CellReady®) is an adipose-derived mesenchymal stem cell therapy categorized under allogeneic cell therapies, developed by Lynch Regenerative Medicine, LLC. The therapy leverages the anti-inflammatory and immunomodulatory properties of mesenchymal stem cells to reduce local inflammation and stimulate tissue regeneration within fistula pathways. By secreting growth factors and cytokines, AdMSC supports structural repair and tract closure. Lynch Regenerative Medicine concentrates on scalable cell processing technologies and clinical translation of regenerative biologics targeting complex gastrointestinal and soft-tissue conditions.

Key Questions Answered in the Digestive System Fistula Pipeline Insight Report

• Which companies/institutions are leading the digestive system fistula drug development?
• Which company is leading the digestive system fistula pipeline development activities?
• What is the current digestive system fistula commercial assessment?
• What are the opportunities and challenges present in the digestive system fistula pipeline landscape?
• What is the efficacy and safety profile of digestive system fistula pipeline drugs?
• Which company is conducting major trials for digestive system fistula drugs?
• Which companies/institutions are involved in digestive system fistula collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in digestive system fistula?

Reasons To Buy This Report

The Digestive System Fistula Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for digestive system fistula. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into digestive system fistula collaborations, regulatory environments, and potential growth opportunities.